# Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Study Guide This study guide provides a comprehensive overview of the updated 2023 American Society of Clinical Oncology (ASCO) clinical practice guidelines regarding the geriatric assessment (GA) and management of older patients with cancer. ## Core Recommendations and Guideline Update The 2023 update was prompted by new "signals" in medical literature—specifically large-scale randomized clinical trials (RCTs)—that demonstrated geriatric assessment-guided management (GAM) significantly reduces chemotherapy-related toxicities. ### Key Recommendations | Recommendation | Description | | :--- | :--- | | **Recommendation 1.1** | All patients with cancer aged 65 and over with GA-identified impairments should have **Geriatric Assessment-guided Management (GAM)** included in their care plan. | | **Amendment 1.1a** | This recommendation applies to older adults receiving all forms of **systemic therapy**, including chemotherapy, targeted therapy, or immunotherapy. | | **Recommendation 2.1** | A GA should include high-priority aging-related domains: physical and cognitive function, emotional health, comorbid conditions, polypharmacy, nutrition, and social support. | | **Recommendation 2.2** | The **Practical Geriatric Assessment (PGA)** is recommended as one option for identifying vulnerabilities in clinical practice. | | **Recommendation 3** | Clinicians should estimate life expectancy (LE) of 4+ years using validated tools like the **Schonberg or Lee Indices** to consider competing risks of mortality. | ## The Practical Geriatric Assessment (PGA) Framework The PGA was developed to address implementation barriers such as time and resource constraints. It uses validated items to screen for impairments and provides specific clinical recommendations. ### PGA Domains and Clinical Thresholds | Domain | Measure/Item | Threshold for Impairment | Recommended Action | | :--- | :--- | :--- | :--- | | **Physical Performance** | Falls in last 6 months | $\ge 1$ fall | Adjust BP meds; provide fall prevention handouts; refer to Physical Therapy (PT). | | **Functional Status** | IADLs (Walking, meals, money, etc.) | Any item with "some help" or "unable" | Consider single-agent therapy; 20% dose reduction; more frequent toxicity checks. | | **Nutrition** | Weight loss in last 3 months | Loss $> 3$ kg (6.6 lbs) | Refer to dietician/nutritionist; liberalize calorie-restricted diets; consider appetite meds. | | **Social Support** | MOS Social Support Survey | Any item with "none" or "a little" of the time | Refer to social work; confirm health care proxy; assess for elder abuse. | | **Psychological** | PROMIS Anxiety / GDS-5 | Score $\ge 11$ (Anxiety) or $\ge 2$ (Depression) | Refer to psycho-oncology, psychiatry, or spiritual counseling. | | **Cognitive Function** | Mini-Cog | Score 0–2 | Provide written instructions; elicit caregiver input; assess decision-making capacity. | | **Comorbidity** | OARS Comorbidity | $\ge 3$ conditions | Communicate with Primary Care Physician (PCP); avoid neurotoxic agents in diabetics. | ## Evidence Base: Summary of Key Clinical Trials The guideline update is supported by several pivotal trials evaluating the efficacy of GA and GAM. * **GAP70+:** Enrolled patients 70+ with advanced cancer. Found that GAM reduced grade 3–5 toxic effects from 71% (usual care) to 51% (intervention arm). It also led to fewer falls and reduced polypharmacy. * **GAIN:** Enrolled patients 65+ with solid tumors. Demonstrated a 10.1% reduction in grade 3+ chemotherapy-related toxic effects and a significant increase in advance directive completion. * **INTEGERATE:** Focused on quality of life (QOL). Found that integrated oncogeriatric care improved HRQOL over 24 weeks and reduced unplanned hospital admissions. * **COACH:** Evaluated communication. Proved that providing a GA summary to oncologists increased satisfaction with communication regarding aging-related concerns for both patients and caregivers. * **GERICO:** Found that GA-based interventions increased the percentage of patients completing scheduled chemotherapy without dose modifications (45% vs. 28% in standard care). ## Implementation Barriers and Practice Considerations Despite high-quality evidence, the uptake of GA in clinical practice remains modest. 1. **Reported Barriers:** The most common obstacles include the time required to perform assessments, lack of adequate resources (staffing and financial), and a lack of specific training or knowledge of GA tools. 2. **Clinical Interpretation:** GAM improves outcomes by optimizing care through treatment modifications (e.g., dose adjustments) and multidisciplinary interventions (e.g., referrals to PT, nutrition, or social work). 3. **Communication:** GA results should be used to facilitate shared decision-making, helping to avoid both the overtreatment of frail patients and the undertreatment of fit patients. --- ## Short-Answer Practice Questions 1. **What is the minimum age threshold at which the ASCO guideline recommends conducting a Geriatric Assessment?** 2. **How does the 2023 update expand the scope of the 2018 guideline regarding the types of cancer treatments covered?** 3. **According to the GAP70+ trial, what was the percentage reduction in grade 3–5 toxic effects for patients in the GAM intervention arm compared to usual care?** 4. **Identify three high-priority aging-related domains that must be included in a GA according to Recommendation 2.1.** 5. **Which two specific indices does the Expert Panel recommend for estimating non-cancer life expectancy?** 6. **What clinical threshold in the Mini-Cog indicates a high likelihood of cognitive impairment?** 7. **In the GAIN trial, which secondary outcome showed a significant increase in the intervention arm compared to standard care?** 8. **What is the primary purpose of the Practical Geriatric Assessment (PGA) tool compared to more comprehensive assessments?** --- ## Essay Prompts for Deeper Exploration 1. **The Shift from Assessment to Management:** Discuss the clinical significance of moving from simply performing a Geriatric Assessment (GA) to implementing Geriatric Assessment-guided Management (GAM). Use evidence from the GAP70+ and GAIN trials to support your argument. 2. **Overcoming Implementation Barriers:** Analyze the primary barriers to the routine use of GA in oncology practices identified in the source text. Evaluate how the development of the Practical Geriatric Assessment (PGA) addresses these challenges. 3. **Systemic Therapy and the Older Adult:** Explore the rationale for including immunotherapy and targeted therapy in the updated guidelines. Why is GA-guided care relevant for these newer treatments despite the historical focus on traditional chemotherapy? 4. **Equity in Geriatric Oncology:** The guideline identifies a "non-representative nature" in current clinical trial enrollment for older adults. Discuss how the widespread adoption of GA might help narrow the gap in health equity and improve clinical trial accrual for vulnerable populations. --- ## Glossary of Important Terms * **Activities of Daily Living (ADL):** Basic self-care tasks, such as dressing, bathing, and getting in or out of bed. * **CARG Toxicity Tool:** An 11-item tool used to calculate the risk of chemotherapy toxicity based on sociodemographics, tumor/treatment variables, laboratory results, and GA variables. * **Geriatric Assessment (GA):** A multidimensional assessment used to identify vulnerabilities or impairments (physical, cognitive, emotional, etc.) not captured in routine oncology assessments. * **Geriatric Assessment-guided Management (GAM):** The use of GA results to inform treatment decisions and implement targeted interventions, counseling, or referrals. * **Instrumental Activities of Daily Living (IADL):** Complex tasks required for independent living, such as managing money, using transportation, preparing meals, and housework. * **Palliative Intent:** Treatment focused on relieving symptoms and improving quality of life rather than curing the disease. * **Polypharmacy:** The concurrent use of multiple medications by a patient, which GA aims to reduce to prevent adverse interactions. * **Practical Geriatric Assessment (PGA):** A streamlined, consensus-based GA tool designed for efficient use in various clinical settings to identify targets for intervention. * **Systemic Therapy:** Cancer treatments that travel through the blood to reach cells throughout the body, including chemotherapy, targeted therapy, and immunotherapy.